Header Logo

Connection

Patrick Arbuthnot to Humans

Back to Details
This is a "connection" page, showing publications Patrick Arbuthnot has written about Humans.
Patrick Arbuthnot
Connection Strength
2,008
Humans
  1. Hepatitis B Virus Research in South Africa. Viruses. 2022 08 31; 14(9).
    View in: PubMed
    Score: 0,064
  2. Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets. 2021 06; 25(6):451-466.
    View in: PubMed
    Score: 0,058
  3. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021 Apr; 28(3-4):117-129.
    View in: PubMed
    Score: 0,056
  4. Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses. 2020 08 04; 12(8).
    View in: PubMed
    Score: 0,055
  5. Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus. Curr Opin HIV AIDS. 2020 05; 15(3):200-207.
    View in: PubMed
    Score: 0,054
  6. Generating DNA Expression Cassettes Encoding Multimeric Artificial MicroRNA Precursors. Methods Mol Biol. 2020; 2115:185-197.
    View in: PubMed
    Score: 0,053
  7. Gene and cell therapy in South Africa: Current status and future prospects. S Afr Med J. 2019 Sep 10; 109(8b):12-16.
    View in: PubMed
    Score: 0,052
  8. How successful has targeted RNA interference for hepatic fibrosis been? Expert Opin Biol Ther. 2018 04; 18(4):381-388.
    View in: PubMed
    Score: 0,046
  9. ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells. Sci Rep. 2017 08 07; 7(1):7401.
    View in: PubMed
    Score: 0,045
  10. The state of gene therapy research in Africa, its significance and implications for the future. Gene Ther. 2017 09; 24(9):581-589.
    View in: PubMed
    Score: 0,045
  11. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res. 2018 01 15; 244:311-320.
    View in: PubMed
    Score: 0,043
  12. A T7 Endonuclease I Assay to Detect Talen-Mediated Targeted Mutation of HBV cccDNA. Methods Mol Biol. 2017; 1540:85-95.
    View in: PubMed
    Score: 0,043
  13. Activating the innate immune response to counter chronic hepatitis B virus infection. Expert Opin Biol Ther. 2016 12; 16(12):1517-1527.
    View in: PubMed
    Score: 0,042
  14. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Mol Ther. 2016 Apr; 24(4):671-7.
    View in: PubMed
    Score: 0,041
  15. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus. Discov Med. 2015 Sep; 20(109):137-43.
    View in: PubMed
    Score: 0,039
  16. The role of long non-coding RNAs in hepatitis B virus-related hepatocellular carcinoma. Virus Res. 2016 Jan 02; 212:103-13.
    View in: PubMed
    Score: 0,039
  17. Progress and Prospects of Anti-HBV Gene Therapy Development. Int J Mol Sci. 2015 Jul 31; 16(8):17589-610.
    View in: PubMed
    Score: 0,039
  18. Use of guanidinopropyl-modified siRNAs to silence gene expression. Methods Mol Biol. 2015; 1218:217-49.
    View in: PubMed
    Score: 0,037
  19. Recent advances in use of gene therapy to treat hepatitis B virus infection. Adv Exp Med Biol. 2015; 848:31-49.
    View in: PubMed
    Score: 0,037
  20. Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses. Gene Ther. 2015 Feb; 22(2):163-71.
    View in: PubMed
    Score: 0,037
  21. Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter. Biomed Res Int. 2014; 2014:718743.
    View in: PubMed
    Score: 0,036
  22. Inhibition of HBV replication in vivo using helper-dependent adenovirus vectors to deliver antiviral RNA interference expression cassettes. Antivir Ther. 2014; 19(4):363-73.
    View in: PubMed
    Score: 0,035
  23. Recent advances in developing nucleic acid-based HBV therapy. Future Microbiol. 2013 Nov; 8(11):1489-504.
    View in: PubMed
    Score: 0,035
  24. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther. 2013 Oct; 21(10):1889-97.
    View in: PubMed
    Score: 0,034
  25. Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2'-O-guanidinopropyl modified siRNAs. Bioorg Med Chem. 2013 Oct 15; 21(20):6145-55.
    View in: PubMed
    Score: 0,033
  26. Efficient silencing of hepatitis B virus by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs. Microrna. 2012; 1(1):19-25.
    View in: PubMed
    Score: 0,030
  27. Countering hepatitis B virus infection using RNAi: how far are we from the clinic? Rev Med Virol. 2011 Nov; 21(6):383-96.
    View in: PubMed
    Score: 0,030
  28. MicroRNA-like antivirals. Biochim Biophys Acta. 2011 Nov-Dec; 1809(11-12):746-55.
    View in: PubMed
    Score: 0,029
  29. Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators. Expert Opin Drug Deliv. 2010 Dec; 7(12):1373-85.
    View in: PubMed
    Score: 0,028
  30. tRNA Lys3 promoter cassettes that efficiently express RNAi-activating antihepatitis B virus short hairpin RNAs. Biochem Biophys Res Commun. 2010 Aug 06; 398(4):640-6.
    View in: PubMed
    Score: 0,027
  31. Harnessing RNA interference for the treatment of viral infections. Drug News Perspect. 2010 Jul-Aug; 23(6):341-50.
    View in: PubMed
    Score: 0,027
  32. Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro-RNA shuttles. Biochem Biophys Res Commun. 2009 Nov 20; 389(3):484-9.
    View in: PubMed
    Score: 0,026
  33. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Res. 2009 Jul; 37(13):e91.
    View in: PubMed
    Score: 0,025
  34. Hepatic delivery of RNA interference activators for therapeutic application. Curr Gene Ther. 2009 Apr; 9(2):91-103.
    View in: PubMed
    Score: 0,025
  35. Efficient nucleic acid transduction with lipoplexes containing novel piperazine- and polyamine-conjugated cholesterol derivatives. Bioorg Med Chem Lett. 2009 Jan 01; 19(1):100-3.
    View in: PubMed
    Score: 0,024
  36. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther. 2008 Jun; 16(6):1105-12.
    View in: PubMed
    Score: 0,024
  37. Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World J Gastroenterol. 2008 Mar 21; 14(11):1670-81.
    View in: PubMed
    Score: 0,023
  38. Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. J Viral Hepat. 2007 Jul; 14(7):447-59.
    View in: PubMed
    Score: 0,022
  39. Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther. 2007 Mar; 15(3):534-41.
    View in: PubMed
    Score: 0,022
  40. Effective anti-hepatitis B virus hammerhead ribozymes derived from multimeric precursors. Oligonucleotides. 2007; 17(1):104-12.
    View in: PubMed
    Score: 0,022
  41. Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. AIDS Res Hum Retroviruses. 2006 May; 22(5):401-10.
    View in: PubMed
    Score: 0,021
  42. Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther. 2006 Feb; 13(2):411-21.
    View in: PubMed
    Score: 0,020
  43. Exploiting the RNA interference pathway to counter hepatitis B virus replication. Liver Int. 2005 Feb; 25(1):9-15.
    View in: PubMed
    Score: 0,019
  44. Hepatitis B virus X protein does not influence essential steps of nucleotide excision repair effected by human liver extracts. Biochem Biophys Res Commun. 2003 Dec 19; 312(3):806-10.
    View in: PubMed
    Score: 0,017
  45. Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa. Lancet Infect Dis. 2023 08; 23(8):e288-e300.
    View in: PubMed
    Score: 0,017
  46. Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics. Genes (Basel). 2022 10 25; 13(11).
    View in: PubMed
    Score: 0,016
  47. Advancing mRNA technologies for therapies and vaccines: An African context. Front Immunol. 2022; 13:1018961.
    View in: PubMed
    Score: 0,016
  48. Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells. Anticancer Res. 2002 Jul-Aug; 22(4):2253-9.
    View in: PubMed
    Score: 0,016
  49. Nucleotide excision repair by extracts of human fetal hepatocytes. FEBS Lett. 2002 May 08; 518(1-3):144-8.
    View in: PubMed
    Score: 0,016
  50. Diversity of Dysregulated Long Non-Coding RNAs in HBV-Related Hepatocellular Carcinoma. Front Immunol. 2022; 13:834650.
    View in: PubMed
    Score: 0,015
  51. In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors. Viruses. 2021 11 09; 13(11).
    View in: PubMed
    Score: 0,015
  52. Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains. Viruses. 2021 07 12; 13(7).
    View in: PubMed
    Score: 0,015
  53. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach. World J Gastroenterol. 2021 Jun 21; 27(23):3182-3207.
    View in: PubMed
    Score: 0,015
  54. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol. 2001 Apr; 82(2):77-100.
    View in: PubMed
    Score: 0,014
  55. Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells. Gene Ther. 2021 09; 28(9):602-612.
    View in: PubMed
    Score: 0,014
  56. Hammerhead ribozyme-mediated inhibition of hepatitis B virus X gene expression in cultured cells. J Hepatol. 2000 Jul; 33(1):142-51.
    View in: PubMed
    Score: 0,014
  57. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol. 2000 Apr; 15(4):357-68.
    View in: PubMed
    Score: 0,013
  58. In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem Biophys Res Commun. 2000 Feb 24; 268(3):728-33.
    View in: PubMed
    Score: 0,013
  59. In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs Using an Ancestral Adeno-Associated Viral Vector. Methods Mol Biol. 2020; 2115:171-183.
    View in: PubMed
    Score: 0,013
  60. Site-directed mutagenesis by fusion of contiguous DNA fragments. Biotechniques. 1999 Mar; 26(3):382-4, 386.
    View in: PubMed
    Score: 0,013
  61. Longitudinal in vivo bioimaging of hepatocyte transcription factor activity following cholestatic liver injury in mice. Sci Rep. 2017 02 03; 7:41874.
    View in: PubMed
    Score: 0,011
  62. Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus. Biochem Biophys Res Commun. 2016 09 30; 478(4):1563-8.
    View in: PubMed
    Score: 0,011
  63. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther. 1996 Aug 20; 7(13):1503-14.
    View in: PubMed
    Score: 0,010
  64. Successful disabling of the 5' UTR of HCV using adeno-associated viral vectors to deliver modular multimeric primary microRNA mimics. J Virol Methods. 2016 09; 235:26-33.
    View in: PubMed
    Score: 0,010
  65. Spacer Length: A Determining Factor in the Design of Galactosyl Ligands for Hepatoma Cell-Specific Liposomal Gene Delivery. Curr Drug Deliv. 2016; 13(6):935-45.
    View in: PubMed
    Score: 0,010
  66. Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences. Hepatology. 1995 Dec; 22(6):1788-96.
    View in: PubMed
    Score: 0,010
  67. In vivo bioimaging with tissue-specific transcription factor activated luciferase reporters. Sci Rep. 2015 Jul 03; 5:11842.
    View in: PubMed
    Score: 0,010
  68. Stealth lipoplex decorated with triazole-tethered galactosyl moieties: a strong hepatotropic gene vector. Biotechnol Lett. 2015 Mar; 37(3):567-75.
    View in: PubMed
    Score: 0,009
  69. Specific micro RNA-regulated TetR-KRAB transcriptional control of transgene expression in viral vector-transduced cells. PLoS One. 2012; 7(12):e51952.
    View in: PubMed
    Score: 0,008
  70. Impact of sustained RNAi-mediated suppression of cellular cofactor Tat-SF1 on HIV-1 replication in CD4+ T cells. Virol J. 2012 Nov 15; 9:272.
    View in: PubMed
    Score: 0,008
  71. Pathogenic effects of Rift Valley fever virus NSs gene are alleviated in cultured cells by expressed antiviral short hairpin RNAs. Antivir Ther. 2012; 17(4):643-56.
    View in: PubMed
    Score: 0,008
  72. Synthesis of 2'-O-guanidinopropyl-modified nucleoside phosphoramidites and their incorporation into siRNAs targeting hepatitis B virus. Bioorg Med Chem. 2012 Feb 15; 20(4):1594-606.
    View in: PubMed
    Score: 0,008
  73. c-fos and c-myc oncoprotein expression in human hepatocellular carcinomas. Anticancer Res. 1991 Mar-Apr; 11(2):921-4.
    View in: PubMed
    Score: 0,007
  74. Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors. Nucleic Acids Res. 2010 Oct; 38(19):6652-63.
    View in: PubMed
    Score: 0,007
  75. Effective Pol III-expressed long hairpin RNAs targeted to multiple unique sites of HIV-1. Methods Mol Biol. 2010; 629:159-74.
    View in: PubMed
    Score: 0,007
  76. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release. 2010 Apr 19; 143(2):222-32.
    View in: PubMed
    Score: 0,007
  77. Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. Int J Cancer. 2009 Oct 15; 125(8):1894-901.
    View in: PubMed
    Score: 0,007
  78. Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS One. 2009 Sep 30; 4(9):e7232.
    View in: PubMed
    Score: 0,007
  79. Expression of c-erbA in human hepatocellular carcinomas. Anticancer Res. 1989 Jul-Aug; 9(4):885-7.
    View in: PubMed
    Score: 0,006
  80. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm. 2009 May-Jun; 6(3):706-17.
    View in: PubMed
    Score: 0,006
  81. The efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA. PLoS One. 2008 Jul 02; 3(7):e2602.
    View in: PubMed
    Score: 0,006
  82. Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. Hepatology. 2007 Jun; 45(6):1390-9.
    View in: PubMed
    Score: 0,006
  83. The inhibitory efficacy of RNA POL III-expressed long hairpin RNAs targeted to untranslated regions of the HIV-1 5' long terminal repeat. Oligonucleotides. 2007; 17(4):419-31.
    View in: PubMed
    Score: 0,005
  84. Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of beta-catenin. Hepatology. 2006 Mar; 43(3):415-24.
    View in: PubMed
    Score: 0,005
  85. Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene. 2006 Feb 16; 25(7):1008-17.
    View in: PubMed
    Score: 0,005
  86. Human S15a expression is upregulated by hepatitis B virus X protein. Mol Carcinog. 2004 May; 40(1):34-46.
    View in: PubMed
    Score: 0,004
  87. Upregulated expression of a unique gene by hepatitis B x antigen promotes hepatocellular growth and tumorigenesis. Neoplasia. 2003 May-Jun; 5(3):229-44.
    View in: PubMed
    Score: 0,004
  88. Hepatitis Bx antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia. 2002 Jul-Aug; 4(4):355-68.
    View in: PubMed
    Score: 0,004
  89. A cellular gene up-regulated by hepatitis B virus-encoded X antigen promotes hepatocellular growth and survival. Hepatology. 2001 Jul; 34(1):146-57.
    View in: PubMed
    Score: 0,004
  90. The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis. Oncogene. 1999 Mar 04; 18(9):1677-87.
    View in: PubMed
    Score: 0,003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.